INCB040093 & INCB040093 Combined With Itacitinib (INCB039110) in

See also
Status	Clinical Trial	Phase
Completed	`NCT00005803` - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03259503` - Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	Phase 1
Completed	`NCT04052997` - Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Recruiting	`NCT04134325` - Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma	Early Phase 1
Completed	`NCT01921387` - Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	Phase 1/Phase 2
Completed	`NCT01701986` - Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT00075478` - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 3
Withdrawn	`NCT03739606` - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Phase 2
Completed	`NCT01393717` - Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma	Phase 2
Recruiting	`NCT05595447` - Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma	Phase 2/Phase 3
Completed	`NCT00789776` - Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT02227199` - Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05272384` - Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	Phase 1
Active, not recruiting	`NCT03739619` - Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT02869633` - Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Phase 2
Completed	`NCT01231412` - Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Phase 3
Recruiting	`NCT04871607` - Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma	Phase 2
Active, not recruiting	`NCT04681105` - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Phase 1
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT03013933` - Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	Phase 1

NCT number	NCT02456675
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2015
Completion date	December 16, 2016

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms